For the year ending 2025-12-31, IOVA had $47,005K increase in cash & cash equivalents over the period. -$336,244K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net sales | 263,502 |
| Cost of goods sold (excluding depreciation and amortization) | 155,809 |
| Stock-based compensation | 7,286 |
| Royalties | 10,089 |
| Total cost of sales | 173,184 |
| Research and development | 273,311 |
| General and administrative | 73,537 |
| Sales and marketing | 51,455 |
| Depreciation and amortization | 35,939 |
| Restructuring charges | 5,143 |
| Other segment items | 41,911 |
| Total expenses | 481,296 |
| Net loss | -390,978 |
| Stock-based compensation expense | 61,575 |
| Unrealized foreign exchange loss | 238 |
| Amortization of intangible assets | 23,077 |
| Amortization of right of use asset | 11,385 |
| Depreciation and amortization of property and equipment | 12,862 |
| Deferred tax (benefit) expense | -2,071 |
| Excess and obsolescence reserve | 13,404 |
| Accretion of discounts and premiums on investments | 7,202 |
| Loss on asset disposals | -44 |
| Prepaid expenses, other assets and long-term assets | 8,023 |
| Trade accounts receivable | 13,108 |
| Inventory | 14,211 |
| Operating lease liabilities | -10,900 |
| Accounts payable | -6,661 |
| Accrued expenses and other liabilities | 28,637 |
| Net cash used in operating activities | -302,408 |
| Maturities of investments | 400,000 |
| Purchase of investments | 318,668 |
| Purchase of property and equipment | 33,836 |
| Net cash provided by (used in) investing activities | 47,496 |
| Tax payments related to shares withheld for vested restricted stock units | 7,059 |
| Proceeds from the issuance of common stock under employee stock purchase plan | 1,510 |
| Proceeds from the issuance of common stock upon exercise of options | 15 |
| Proceeds from the issuance of common stock, net | 306,307 |
| Net cash provided by financing activities | 300,773 |
| Effect of foreign exchange rate changes | 1,144 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 47,005 |
| Cash, cash equivalents and restricted cash beginning of period | 122,053 |
| Cash, cash equivalents and restricted cash end of period | 169,058 |
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
IOVANCE BIOTHERAPEUTICS, INC. (IOVA)